BARCELONA, Spain and CAMBRIDGEMassachusettsJuly 17, 2018 — SOM Biotech, a clinical-stage biopharmaceutical company that discovers and develops drugs for orphan indications in the Central Nervous System, has announced today the successful initiation of Phase 2a clinical trial of its repurposed compound SOM3355 for the treatment of the chorea movements associated to Huntington’s disease.

The Principal Investigator of the study is Dr. Jaume Kulisevsky from Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Other participating sites, also located in Barcelona, are Hospital Universitari de Bellvitge, Hospital Clínic de Barcelona and Hospital Universitari Vall d’Hebron, with leading neurologist investigators Dr. Matilde Calopa Garriga, Dr. Esteban Muñoz and Dr. Josep Gàmez, respectively.

Read the full press release here.

Press Release English

Press Release Spanish

Press Release Catalan

SUBCRIBE TO OUR NEWSLETTER

    Name*
    Email*


    I confirm that by completing this form I have used only personal data about myself and that they are true and up-to-date.
    SOM INNOVATION BIOTECH, S.A. is responsible for the processing of my personal data to manage the newsletter service requested through the form, as well as to track the receipt of these through tracking technologies. The Privacy Policy tells me how I can exercise my rights of access, rectification, deletion, limitation, portability and opposition.